3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Breast Neoplasms
9
Prostatic Neoplasms
6
Melanoma
6
Colorectal Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Rectal Neoplasms
4
Neoplasm Metastasis
4
Multiple Myeloma
4
Mouth Neoplasms
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Neoplasms
3
Head and Neck Neoplasms
3
Colonic Neoplasms
3
Uterine Cervical Dysplasia
2
Skin Neoplasms
2
Sarcoma, Kaposi
2
Sarcoma
2
Pancreatic Neoplasms
2
Oropharyngeal Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Inflammatory Breast Neoplasms
2
HIV Infections
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Turcot syndrome
1
Thrombocytosis
1
Interventions
Epoetin Alfa
9
Darbepoetin alfa
5
epoetin beta
3
telapristone acetate
2
fludarabine phosphate
2
fludarabine
2
Cyclophosphamide
2
Carboplatin
2
Busulfan
2
AP 1903 reagent
2
ACE-011
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
venetoclax
1
vactosertib
1
trametinib
1
thymoglobulin
1
ruxolitinib
1
regorafenib
1
ponatinib
1
pertuzumab
1
pembrolizumab
1
peginesatide
1
palbociclib
1
olaparib
1
niraparib
1
neratinib
1
lorlatinib
1
lenvatinib
1
idelalisib
1
hematide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Anemia
×
Biopsy
×
Clear all
NCT02452983
2022-06-02
SS1
Baylor College of Medicine
Phase 1
Terminated
14 enrolled